SCHEMBL3000836

SCHEMBL3000836

CC(=O)Nc1ccc(N)cc1C#N

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.47
ALDH1A1 P00352 4/20 0.45
KDM4E B2RXH2 3/20 0.45
USP2 O75604 1/20 0.45
HTT P42858 1/20 0.43
GAA P10253 1/20 0.43
HPGD P15428 1/20 0.43
MAPT P10636 2/20 0.42
POLB P06746 1/20 0.42
RAB9A P51151 1/20 0.42
CA1 P00915 4/20 0.42
CA2 P00918 4/20 0.42
CA9 Q16790 4/20 0.42
CLK1 P49759 1/20 0.40
NEU3 Q9UQ49 1/20 0.40
RECQL P46063 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2342976 0.87 ALDH1A1 (0.48) NPC1ALDH1A1KDM4EUSP2HTT
SCHEMBL11739899 0.82 GPR35 (0.47) ALDH1A1KDM4EUSP2GAAHPGD
SCHEMBL4806828 0.81 ALDH1A1 (0.54) NPC1ALDH1A1KDM4EHTTGAA
SCHEMBL3000834 0.81 NEU3 (0.48) NPC1ALDH1A1KDM4EHTTGAA
SCHEMBL11508737 0.81 MAPT (0.51) NPC1GAAMAPTPOLBRAB9A
SCHEMBL24022846 0.80 MOK (0.47) NPC1ALDH1A1KDM4EHTTGAA
SCHEMBL9224255 0.80 ALDH1A1 (0.44) NPC1ALDH1A1KDM4EHTTGAA
SCHEMBL10777773 0.80 ALDH1A1 (0.48) NPC1ALDH1A1KDM4EHTTGAA
SCHEMBL6177644 0.80 KDM4E (0.57) NPC1ALDH1A1KDM4EHTTGAA
SCHEMBL6814419 0.80 ABCC9 (0.46) ALDH1A1KDM4EUSP2HTTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190773-A1 Anti-Cytokine Heterocyclic Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-07-29 US claimed
US-20060276496-A1 Anti-Cytokine Heterocyclic Compounds BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-12-07 US claimed
US-20060276453-A1 Anti-Cytokine Heterocyclic Compounds BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-12-07 US claimed
US-7790712-B2 Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors BOEHRINGER INGELHEIM PHARMACEUTICAL, INC. (US) 2010-09-07 US disclosed
US-20100190773-A1 Anti-Cytokine Heterocyclic Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-07-29 US disclosed
US-20060276496-A1 Anti-Cytokine Heterocyclic Compounds BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-12-07 US disclosed
US-20060276453-A1 Anti-Cytokine Heterocyclic Compounds BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-12-07 US disclosed
US-20030036653-A1 Diaminopyridine-containing thiourea inhibitors of herpes viruses AMERICAN HOME PRODUCTS CORPORATION 2003-02-20 US disclosed
US-20020026055-A1 Aminopyridine-containing thiourea inhibitors of herpes viruses AMERICAN HOME PRODUCTS CORPORATION 2002-02-28 US disclosed
US-20010039348-A1 Alpha-methylbenzyl-containing thiourea inhibitors of herpes viruses containing a phenylenediamine group AMERICAN HOME PRODUCTS CORPORATION (US) 2001-11-08 US disclosed
EP-0039312-B1 COLOUR PHOTOPGRAPHIC MATERIAL FOR THE SILVER-DYE BLEACHING PROCESS, PROCESS FOR THE PRODUCTION OF THIS MATERIAL AND ITS USE IN THE PRODUCTION OF PHOTOGRAPHIC IMAGES CIBA-GEIGY AG (CH) 1983-12-28 EP disclosed
US-4379819-A OIL SOLUBLE MONOAZO DYE CIBA-GEIGY AG (CH) 1983-04-12 US disclosed
EP-0039312-A1 Colour photopgraphic material for the silver-dye bleaching process, process for the production of this material and its use in the production of photographic images CIBA-GEIGY AG (CH) 1981-11-04 EP disclosed
US-4062838-A LACQUERS, PRINTING INKS, YELLOW TO ORANGE CIBA-GEIGY CORPORATION (US) 1977-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276496-A1 Anti-Cytokine Heterocyclic Compounds MAPKAPK2, MAP4K2, MAP3K2 NPC1 4214/4885ALDH1A1 3894/4885KDM4E 2943/4885
US-20030036653-A1 Diaminopyridine-containing thiourea inhibitors of herpes viruses HAVCR2, CCR6, CXCR6 NPC1 1705/4885ALDH1A1 3447/4885KDM4E 2975/4885
US-20100190773-A1 Anti-Cytokine Heterocyclic Compounds MAPKAPK2, MAP4K2, MAP3K2 NPC1 4214/4885ALDH1A1 3894/4885KDM4E 2943/4885
US-20010039348-A1 Alpha-methylbenzyl-containing thiourea inhibitors of herpes viruses containing a phenylenediamine group CCR6, HAVCR2, BCOR NPC1 797/4885ALDH1A1 3620/4885KDM4E 1441/4885
US-20020026055-A1 Aminopyridine-containing thiourea inhibitors of herpes viruses TK1, TPMT, CXCR6 NPC1 1212/4885ALDH1A1 3601/4885KDM4E 225/4885
US-20060276453-A1 Anti-Cytokine Heterocyclic Compounds MAPKAPK2, MAP4K2, MAP3K2 NPC1 4214/4885ALDH1A1 3894/4885KDM4E 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.